Date: 2015-07-02
Type of information: Grant
Company: Horama (France)
Investors: French ministry for higher education and research (France)
Amount: € 150,000
Funding type: grant
Planned used: Horama, created in March 2014, is a company dedicated to gene therapy for the treatment of rare genetic diseases in ophthalmology for which no treatment exists to date. This grant will allow Horama to start the pharmaceutical development of its second product HORARLPB1 with the centre UMR 1089 AGT (Atlantic Gene Therapy) in Nantes. This product has discovered by the team of professor Christian Hamel in Inserm U 1051 – Institute Neurosciences of Montpellier and aims to treat retinitis punctata albescences, a rare genetic disease characterized by night blindness from infancy, decreased visual acuity and presence of tiny white deposits and patches of atrophy in peripheral retina. Toxicological studies are ongoing with Horama\'s first product, HORA-PDE6B and the development of the product continues, thanks to financing of BPIFrance obtained last March.
Others: * On July 2nd, 2015, Horama announced it has obtained a subsidy of 150,000 € as a I-Lab prize winner in the category “Creation-Development”.
Therapeutic area: Ophtalmological diseases
